These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19220172)

  • 1. Oestrogen--a new treatment approach for schizophrenia?
    Kulkarni J
    Med J Aust; 2009 Feb; 190(S4):S37-8. PubMed ID: 19220172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in depression with oestrogen treatment in women with schizophrenia.
    Lascurain MB; Camuñas-Palacín A; Thomas N; Breadon C; Gavrilidis E; Hudaib AR; Gurvich C; Kulkarni J
    Arch Womens Ment Health; 2020 Apr; 23(2):149-154. PubMed ID: 30903287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Main risk factors for schizophrenia: increased familial loading and pre- and peri-natal complications antagonize the protective effect of oestrogen in women.
    Könnecke R; Häfner H; Maurer K; Löffler W; an der Heiden W
    Schizophr Res; 2000 Jul; 44(1):81-93. PubMed ID: 10867314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormones and schizophrenia.
    Kulkarni J; Hayes E; Gavrilidis E
    Curr Opin Psychiatry; 2012 Mar; 25(2):89-95. PubMed ID: 22249082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is oestrogen neuroprotective?
    Agius M; Hockings H; Wilson C; Lane D
    Psychiatr Danub; 2009 Sep; 21 Suppl 1():120-7. PubMed ID: 19789496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinical trial of adjunctive oestrogen treatment in women with schizophrenia.
    Kulkarni J; Riedel A; de Castella AR; Fitzgerald PB; Rolfe TJ; Taffe J; Burger H
    Arch Womens Ment Health; 2002 Nov; 5(3):99-104. PubMed ID: 12510212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term oral oestrogen therapy dissociates the growth hormone/insulin-like growth factor-I axis without altering energy metabolism in premenopausal women.
    Huang DS; O'Sullivan AJ
    Growth Horm IGF Res; 2009 Apr; 19(2):162-7. PubMed ID: 18835735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding.
    Lethaby A; Suckling J; Barlow D; Farquhar CM; Jepson RG; Roberts H
    Cochrane Database Syst Rev; 2004; (3):CD000402. PubMed ID: 15266429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender and the use of neuroleptics in schizophrenia.
    Salokangas RK
    Schizophr Res; 2004 Jan; 66(1):41-9. PubMed ID: 14693351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogens and men with schizophrenia: is there a case for adjunctive therapy?
    Kulkarni J; de Castella A; Headey B; Marston N; Sinclair K; Lee S; Gurvich C; Fitzgerald PB; Burger H
    Schizophr Res; 2011 Feb; 125(2-3):278-83. PubMed ID: 21062669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Menstrual cycle characteristics in women with persistent schizophrenia.
    Gleeson PC; Worsley R; Gavrilidis E; Nathoo S; Ng E; Lee S; Kulkarni J
    Aust N Z J Psychiatry; 2016 May; 50(5):481-7. PubMed ID: 26070315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Do estrogens have an antipsychotic action?].
    Riecher-Rössler A; Häfner H; Stumbaum M; Schmidt R
    Fortschr Neurol Psychiatr; 1994 Jan; 62(1):22-8. PubMed ID: 8144127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding.
    Lethaby A; Farquhar C; Sarkis A; Roberts H; Jepson R; Barlow D
    Cochrane Database Syst Rev; 2000; (2):CD000402. PubMed ID: 10796715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender and the use of neuroleptics in schizophrenia. Further testing of the oestrogen hypothesis.
    Salokangas RK
    Schizophr Res; 1995 Jul; 16(1):7-16. PubMed ID: 7547647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Women, schizophrenia and oestrogen; neurobiological hypotheses and hormonetherapy studies].
    Boerma MA; van der Stel JC; van Amelsvoort T; Linszen DH; de Haan L
    Tijdschr Psychiatr; 2010; 52(4):235-44. PubMed ID: 20503164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local oestrogen for vaginal atrophy in postmenopausal women.
    Suckling J; Lethaby A; Kennedy R
    Cochrane Database Syst Rev; 2006 Oct; (4):CD001500. PubMed ID: 17054136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogens and SERMS as adjunctive treatments for schizophrenia.
    Kulkarni J; Butler S; Riecher-Rössler A
    Front Neuroendocrinol; 2019 Apr; 53():100743. PubMed ID: 30922675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oestrogen effects in schizophrenia and their potential therapeutic implications--review.
    Riecher-Rössler A
    Arch Womens Ment Health; 2002 Nov; 5(3):111-8. PubMed ID: 12510214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma BGP: an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women.
    Johansen JS; Riis BJ; Delmas PD; Christiansen C
    Eur J Clin Invest; 1988 Apr; 18(2):191-5. PubMed ID: 2968266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychotic disorders and gonadal function: evidence supporting the oestrogen hypothesis.
    Huber TJ; Borsutzky M; Schneider U; Emrich HM
    Acta Psychiatr Scand; 2004 Apr; 109(4):269-74. PubMed ID: 15008800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.